VW
BIVV

Vantage Wealth’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Vantage Wealth’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,759
Closed -$749K – 26
2017
Q1 		$749K Buy
+13,759
New +$678K 0.41% 24

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Vantage Wealth's BIVV Position: Q2 2017 in Review

Vantage Wealth sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 13,759 shares — an estimated $749K sold.

Vantage Wealth first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $749K in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • Vantage Wealth reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Vantage Wealth sold 13,759 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $749K.
  • Vantage Wealth first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Vantage Wealth's Bioverativ Inc. Common Stock position peaked at $749K in Q1 2017.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on Vantage Wealth's 13F filing for Q2 2017, filed 15 Aug 2017.